Philadelphia University + Thomas Jefferson University

Pollack, Charles

< Back

Profile

Charles V. Pollack, MA, MD

Charles V. Pollack, MA. MD, FACEP, FAAEM, FAHA, FESC, FCPP

Contact Dr. Pollack

1020 Walnut Street
Scott Building, Suite 614
Philadelphia, PA 19107

(215) 503-3105

Medical School

Tulane University School of Medicine - 1984

Residency

University of Mississippi Medical Center - Emergency Medicine
Naval Hospital, San Diego - Preliminary Surgery

Board Certification

Emergency Medicine

Hospital Appointment

Thomas Jefferson University Hospitals

Publications

Most Recent Peer-Reviewed Publications

  1. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
  2. Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban)
  3. The authors reply
  4. Idarucizumab for dabigatran reversal -full cohort analysis
  5. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–ST-segment elevation acute coronary syndrome in the PLATO trial
  6. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study
  7. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
  8. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm
  9. Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention
  10. Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal Agents
  11. Evidence supporting idarucizumab for the reversal of dabigatran
  12. Introduction to direct oral anticoagulants and rationale for specific reversal agents
  13. Evidence Supporting Idarucizumab for the Reversal of Dabigatran
  14. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design
  15. Idarucizumab for dabigatran overdose
  16. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial
  17. Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder
  18. Coagulation assessment with the new generation of oral anticoagulants
  19. Association of early stress testing with outcomes for emergency department evaluation of suspected acute coronary syndrome
  20. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation